title: Occlusion in the Flow of New Drugs for Cardiovascular Disease.
abstract: There is a large misalignment between unmet need and both private and public investment activity in cardiovascular disease. In this paper, we quantify the magnitude of the gap, analyze a range of potential root causes in two main categories (issues of feasibility and valuation), and propose steps toward solutions to close the gap.
authors.affiliation: The Boston Consulting Group, Boston, Massachusetts.
authors.forename: M S
authors.initials: MS
authors.lastname: Ringel
authors.affiliation: The Boston Consulting Group, Summit, New Jersey.
authors.forename: N A
authors.initials: NA
authors.lastname: Shah
authors.affiliation: The Boston Consulting Group, Munich, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Baedeker
authors.affiliation: The Boston Consulting Group, Boston, Massachusetts.
authors.forename: C T
authors.initials: CT
authors.lastname: Lim
authors.affiliation: The Boston Consulting Group, Tokyo, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Lamichhane
authors.affiliation: The Boston Consulting Group, Zurich, Switzerland.
authors.forename: U
authors.initials: U
authors.lastname: Schulze
mesh_terms: D002317:Cardiovascular Agents / Q000191:economics / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics; D055808:Drug Discovery / Q000191:economics / Q000379:methods / Q000639:trends*; D006301:Health Services Needs and Demand / Q000639:trends*; D006801:Humans; D012052:Reimbursement, Incentive / Q000191:economics / Q000639:trends
chemical_list: D002317:Cardiovascular Agents